Author name: Leonardo Arias

The FDA’s refusal to review Moderna’s mRNA-based flu vaccine is part of a larger communications crisis unfolding at the agency over the past nine months that has also ensnarled Sarepta, Capricor, uniQure and many more.

Vinay Prasad, the FDA’s Center for Biologics Evaluation and Research head, is accused of interpersonal impropriety as pushback builds against his decision to reject Moderna’s influenza vaccine candidate.

Taylor Lehmann, a security executive at Google Cloud, discusses the potential cyber risks in AI systems and how healthcare organizations should prepare.

Still, the for-profit hospital operator’s projected loss is less than some of its peers, and Tenet said it expected to grow its earnings in 2026.

La medicina reproductiva ha experimentado avances notables en las últimas décadas, pero pocas herramientas han tenido un impacto tan directo sobre los resultados clínicos como la incorporación de la genética. Dentro de las aportaciones de esta disciplina destaca el …

Moderna’s mRNA-1010 was expected to contribute $1 billion to the company’s coffers by 2028. That plan is now out the window after the FDA refused to even look at the application.

Torres joins the medtech lobby from the FDA’s Center for Devices and Radiological Health, where she was associate director for international affairs.

The device creates lesions to disrupt nerve signals that drive mucus production.

At a House subcommittee hearing on Wednesday, lawmakers on both sides of the aisle decried the nation’s high drug costs, but Democrats argued Medicaid cuts and lapsed Affordable Care Act subsidies are worsening the problem.

Infigratinib topped “even the most optimistic expectations” for efficacy and safety in the late-stage PROPEL 3 study in achondroplasia, Truist Securities analysts said Thursday.